A Pleomorphic Rhabdomyosarcoma Mimicking an Inguinal Hernia: A Case Report and Review of the Literature

Section of Medical Oncology, Second Department of Propaedeutic Internal Medicine, Attikon University Hospital, Athens, Greece.
Case Reports in Oncology 02/2012; 5(1):74-9. DOI: 10.1159/000336158
Source: PubMed

ABSTRACT A 59-year-old male presented with a painful right inguinal swelling and deep vein thrombosis at the ipsilateral leg. An inguinal hernia was initially diagnosed, but during surgery a large mass was found anteriorly to the peritoneal sheaths. Histology revealed a high-grade pleomorphic rhabdomyosarcoma. The mass advanced rapidly, occupying the whole right iliac fossa and metastasizing to the lung. Despite first- and second-line chemotherapy, the patient deteriorated rapidly and died. Rhabdomyosarcomas should be managed in specialized centres as they have prognostic factors and histologic features still controversial and poorly clarified.

Download full-text


Available from: Evangelos P Misiakos, Dec 28, 2013
  • [Show abstract] [Hide abstract]
    ABSTRACT: Histopathologic material from 1,782 patients registered in the Intergroup Rhabdomyosarcoma Study Committee (IRS)-I and -II were reviewed by the IRS Pathology Committee in order to provide a uniform approach to classification and correlate patient survival with tumor type. Categories considered eligible were the four types of rhabdomyosarcoma (RMS) (criteria of Horn and Enterline), extraosseous Ewing's tumor (EOE), and a group of somewhat variable undifferentiated sarcomas designated small round cell sarcoma, type indeterminate (STI). Tumors that were clearly sarcomas but were unclassifiable also were included (NOS). The committee diagnoses were embryonal (Emb) RMS in 877 (54%), alveolar (Alv) RMS in 343 (21%), botryoid (Botr) RMS in 88 (5%), pleomorphic (Pleo) RMS in 11 (1%), STI in 135 (8%), and EOE in 84 (5%). One in nine were mixtures of types, eg, Emb and Alv. Five percent of the sarcomas could not be classified because of inadequate material. In general, there was close agreement (94%) between the review committee and institutional pathologists in the diagnosis of RMS, but not in the specific types, particularly Alv RMS (41%) and STI (36%). This observation is important, since patients with Alv RMS and STI tumors had decreased survival compared with the other histologies. The prognosis varied by histology, with Botr having the best, Alv RMS and STI the worst, and Emb RMS and EOE an intermediate prognosis.
    Journal of Clinical Oncology 02/1988; 6(1):67-75. · 17.88 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: The purpose of our study is to retrospectively review our institutional experience with adult rhabdomyosarcoma (RMS) to determine presentation, prognostic factors and patterns of failure in this disease.Materials and Methods: All patients >/= 16 years with a diagnosis of rhabdomyosarcoma were retrospectively reviewed. Tumors were classified according to the Intergroup Rhabdomyosarcoma Study (IRS) staging and grouping system. Median follow-up for surviving patients was 12.5 years.Results: A total of 39 patients (23 male, 16 female) were seen at our institution from 1961 to 1999. Median age was 45 years, and age distribution showed a bimodal peak at the late teens to twenties and later in the sixties. Tumor in the extremity was most common as seen in 15 (39%); this was followed by head and neck in 11 (28%), genitourinary in eight (20%), trunk/retroperitoneum in four (10%) and other in one (3%). Tumor stage was T1 in 21 (52%) while 26 (67%) were > 5 cm in size. Pleomorphic histology was most common (36%) and increased in incidence according to age category: 0% for ages 16-19, 27% for ages 20-49 and 60% for ages >/= 50 years old (P < 0.01). The median survival for the entire population was 2.25 years with a 5-year overall survival rate of 35%. Multivariate analysis identified early IRS stage (P < 0.001), non-embryonal histology (P < 0.009), favorable site (P = 0.024), female gender (P = 0.034), early T-stage (P = 0.034) and absence of nodal metastases (P = 0.037) as predictors of a better survival. The 5-year progression-free survival rate was 21%. Female gender (P = 0.002), non-embryonal histology (P = 0.009), early IRS stage (P = 0.02) and early T stage (P = 0.033) were found on multivariate analysis to predict for improved progression-free survival. The 5-year local control rate was 51%, and multivariate analysis found that only early T-stage was predictive of better local control (P = 0.045). Five of six Group II patients and five of eight Group III patients who received radiotherapy (RT) were locally controlled. Only one of five Group III patients was locally controlled without RT.Conclusions: The overall prognosis of adult RMS is worse than reported in children, but age criteria within the adult population did not further classify outcome. RT is an effective local modality providing local control in almost all Group II and majority of Group III patients.
    Sarcoma 02/2003; 7(1):1-7. DOI:10.1080/1357714031000114147
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose. To enumerate lessons from studying 4292 patients with rhabdomyosarcoma (RMS) in the Intergroup Rhabdomyosarcoma Study Group (IRSG, 1972–1997). Patients. Untreated patients < 21 years of age at diagnosis received systemic chemotherapy, with or without irradiation (XRT) and/or surgical removal of the tumor. Methods. Pathologic materials and treatment were reviewed to ascertain compliance and to confirm response and relapse status. Results. Survival at 5 years increased from 55 to 71% over the period. Important lessons include the fact that extent of disease at diagnosis affects prognosis. Re-excising an incompletely removed tumor is worthwhile if acceptable form and function can be preserved. The eye, vagina, and bladder can usually be saved. XRT is not necessary for children with localized, completely excised embryonal RMS. Hyperfractionated XRT has thus far not produced superior local control rates compared with conventional, once-daily XRT. Patients with non-metastatic cranial parameningeal sarcoma can usually be cured with localized XRT and systemic chemotherapy, without whole-brain XRT and intrathecal drugs. Adding doxorubicin, cisplatin, etoposide, and ifosfamide has not significantly improved survival of patients with gross residual or metastatic disease beyond that achieved with VAC (vincristine, actinomycin D, cyclophosphamide) and XRT. Most patients with alveolar RMS have a tumor-specific translocation. Mature rhabdomyoblasts after treatment of patients with bladder rhabdomyosarcoma are not necessarily malignant, provided that the tumor has shrunk and malignant cells have disappeared. Discussion. Current IRSG-V protocols, summarized herein, incorporate recommendations for risk-based management. Two new agents, topotecan and irinotecan, are under investigation for patients who have an intermediate or high risk of recurrence.
    Sarcoma 02/2001; 5(1):9-15. DOI:10.1080/13577140120048890